to rivaroxaban (new drug at the institution), primarily based around the recommendation. All consecutive adult oncological outpatients on enoxaparin in the institution had been regarded as eligible for the study. Information on cancer, comorbidities, bleeding, VTE recurrence and death for the duration of 1 year because the 1st stop by had been captured. Cumulative incidence of bleeding and VTE recurrence have been calculated by Kaplan-Meier process and log-rank test. Results: 326 sufferers had been referred for the ambulatory and 275 have been incorporated within the analyses, with a median age of 63 years (IQR 531). 61 have been female. 86 had solid tumours (53 metastatic). The primary web pages have been gastrointestinal (27 ), breast (12 ) and pulmonary (10 ).PB1133|Security and Effectiveness of an Institutional Recommendation around the Management of Cancer Linked Venous Thrombosis: Results of a True Planet Study with One-year Follow-up C. Rothschild; A.A.G.S. Brand ; A. Duran; A.E. Zerati; G.F. Saes; C.S. Bittar; I.B.S.d.S. Costa; M.H.H.d.S. Rehder; S.M.R. Fonseca; M.D.P.E. Diz; L.B.d.O. Alves; J. Pereira; V. Rocha Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, S Paulo, Brazil Background: Management of cancer connected venous thrombosis (CAT) is difficult due to coexistent risk of bleeding and thrombosis (VTE) recurrence, which can be 6 and roughly 4 fold greater when compared with non-cancer patients, respectively. Anticoagulant decision desires to BChE Inhibitor drug become careful and may be guided by a recommendation to avoid those complications. Aims: To evaluate effectiveness and safety of a public cancer institution recommendation on CAT management. Strategies: Retrospective cohort study carried out from October 2018 to January 2020. The recommendation on CAT management45 in the individuals switched to rivaroxaban and five have been in a position to quit anticoagulation. The key reason for not switching was drugdrug interaction (27 ). One-year cumulative incidence of VTE recurrence was 11.two (95 CI 7.76.2) and of general bleeding was 13.4 (95 CI 9.48.7). Significant bleeding occurred in eight sufferers. Death price was 32 , with no one due to bleeding. No significant difference of outcomes was observed between sufferers who had switched or not. Conclusions: Recommendation-based selection on CAT management showed related effectiveness and safety independently of your selected anticoagulant.ABSTRACT833 of|PB1134|Development of a Multi-language Mobile App to Implement the 2019 ITAC Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Cancer Sufferers D. Farge1,2,3; C. Frere1,four; J.M. Connors5,6; C. Ay7; A.A. Khorana8; A. Munoz9,10; B. Brenner11; A. Kakkar12,13; H. Rafii1; S. Solymoss (in memoriam)3; D. Brilhante14; M. Monreal15,16; H. Bounameaux17; I. Pabinger7; J. DouketisFIGURE 1 Multi-language mobile App to implement the International Initiative on Thrombosis and Cancer Clinical Practice H-Ras Inhibitor review Recommendations for the Treatment and Prophylaxis of venous Thromboembolism in Patients with Cancer Conclusions: By translating written ITAC-CPGs into timely and efficient decision-making, the multi-language ITAC app shall permit physicians and other healthcare professionals to overcome cancerassociated management challenges worldwide.Help Publique H itaux de Paris, Paris, France; UniversitdeParis, Paris, France; 3McGill University, Montreal, Canada; 4Sorbonne Universit Paris, France; 5Brigham and Women’s Hospital, Boston, United states of america; 6Harvard Medical College, Boston, United